Hypertension care cascades and reducing inequities in cardiovascular disease in low- and middle-income countries
© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc..
Improving hypertension control in low- and middle-income countries has uncertain implications across socioeconomic groups. In this study, we simulated improvements in the hypertension care cascade and evaluated the distributional benefits across wealth quintiles in 44 low- and middle-income countries using individual-level data from nationally representative, cross-sectional surveys. We raised diagnosis (diagnosis scenario) and treatment (treatment scenario) levels for all wealth quintiles to match the best-performing country quintile and estimated the change in 10-year cardiovascular disease (CVD) risk of individuals initiated on treatment. We observed greater health benefits among bottom wealth quintiles in middle-income countries and in countries with larger baseline disparities in hypertension management. Lower-middle-income countries would see the greatest absolute benefits among the bottom quintiles under the treatment scenario (29.1 CVD cases averted per 1,000 people living with hypertension in the bottom quintile (Q1) versus 17.2 in the top quintile (Q5)), and the proportion of total CVD cases averted would be largest among the lowest quintiles in upper-middle-income countries under both diagnosis (32.0% of averted cases in Q1 versus 11.9% in Q5) and treatment (29.7% of averted cases in Q1 versus 14.0% in Q5) scenarios. Targeted improvements in hypertension diagnosis and treatment could substantially reduce socioeconomic-based inequalities in CVD burden in low- and middle-income countries.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Nature medicine - 30(2024), 2 vom: 27. Feb., Seite 414-423 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stein, Dorit Talia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 22.02.2024 Date Revised 24.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41591-023-02769-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367694069 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367694069 | ||
| 003 | DE-627 | ||
| 005 | 20240229145944.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240127s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41591-023-02769-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1304.xml |
| 035 | |a (DE-627)NLM367694069 | ||
| 035 | |a (NLM)38278990 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stein, Dorit Talia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hypertension care cascades and reducing inequities in cardiovascular disease in low- and middle-income countries |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2024 | ||
| 500 | |a Date Revised 24.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Nature America, Inc. | ||
| 520 | |a Improving hypertension control in low- and middle-income countries has uncertain implications across socioeconomic groups. In this study, we simulated improvements in the hypertension care cascade and evaluated the distributional benefits across wealth quintiles in 44 low- and middle-income countries using individual-level data from nationally representative, cross-sectional surveys. We raised diagnosis (diagnosis scenario) and treatment (treatment scenario) levels for all wealth quintiles to match the best-performing country quintile and estimated the change in 10-year cardiovascular disease (CVD) risk of individuals initiated on treatment. We observed greater health benefits among bottom wealth quintiles in middle-income countries and in countries with larger baseline disparities in hypertension management. Lower-middle-income countries would see the greatest absolute benefits among the bottom quintiles under the treatment scenario (29.1 CVD cases averted per 1,000 people living with hypertension in the bottom quintile (Q1) versus 17.2 in the top quintile (Q5)), and the proportion of total CVD cases averted would be largest among the lowest quintiles in upper-middle-income countries under both diagnosis (32.0% of averted cases in Q1 versus 11.9% in Q5) and treatment (29.7% of averted cases in Q1 versus 14.0% in Q5) scenarios. Targeted improvements in hypertension diagnosis and treatment could substantially reduce socioeconomic-based inequalities in CVD burden in low- and middle-income countries | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Reitsma, Marissa B |e verfasserin |4 aut | |
| 700 | 1 | |a Geldsetzer, Pascal |e verfasserin |4 aut | |
| 700 | 1 | |a Agoudavi, Kokou |e verfasserin |4 aut | |
| 700 | 1 | |a Aryal, Krishna Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Bahendeka, Silver |e verfasserin |4 aut | |
| 700 | 1 | |a Brant, Luisa C C |e verfasserin |4 aut | |
| 700 | 1 | |a Farzadfar, Farshad |e verfasserin |4 aut | |
| 700 | 1 | |a Gurung, Mongal Singh |e verfasserin |4 aut | |
| 700 | 1 | |a Guwatudde, David |e verfasserin |4 aut | |
| 700 | 1 | |a Houehanou, Yessito Corine Nadège |e verfasserin |4 aut | |
| 700 | 1 | |a Malta, Deborah Carvalho |e verfasserin |4 aut | |
| 700 | 1 | |a Martins, João Soares |e verfasserin |4 aut | |
| 700 | 1 | |a Saeedi Moghaddam, Sahar |e verfasserin |4 aut | |
| 700 | 1 | |a Mwangi, Kibachio Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Norov, Bolormaa |e verfasserin |4 aut | |
| 700 | 1 | |a Sturua, Lela |e verfasserin |4 aut | |
| 700 | 1 | |a Zhumadilov, Zhaxybay |e verfasserin |4 aut | |
| 700 | 1 | |a Bärnighausen, Till |e verfasserin |4 aut | |
| 700 | 1 | |a Davies, Justine I |e verfasserin |4 aut | |
| 700 | 1 | |a Flood, David |e verfasserin |4 aut | |
| 700 | 1 | |a Marcus, Maja E |e verfasserin |4 aut | |
| 700 | 1 | |a Theilmann, Michaela |e verfasserin |4 aut | |
| 700 | 1 | |a Vollmer, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Manne-Goehler, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Atun, Rifat |e verfasserin |4 aut | |
| 700 | 1 | |a Sudharsanan, Nikkil |e verfasserin |4 aut | |
| 700 | 1 | |a Verguet, Stéphane |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature medicine |d 1995 |g 30(2024), 2 vom: 27. Feb., Seite 414-423 |w (DE-627)NLM074659804 |x 1546-170X |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:2 |g day:27 |g month:02 |g pages:414-423 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41591-023-02769-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2024 |e 2 |b 27 |c 02 |h 414-423 | ||